论文部分内容阅读
AIM To verify whether recurrence-free survival(RFS) surrogates overall survival(OS) in phase Ⅲ trials for resectable colorectal liver metastases(CRLM).METHODS MEDLINE,EMBASE,and Scopus databases were consulted.Eligible studies were phase Ⅲ trials testing any type of systemic therapy(neoadjuvant,adjuvant or perioperative) added to surgery in patients with resectable CRLM.A linear regression model based on hazard ratios(HR) of OS and RFS was performed.RESULTS Of 3059 studies,5 phase Ⅲ trials(1162 patients) were included for analyses.A linear regression weighted by each trial was used to estimate the association between each HR and RFS.The originated formula was:OS HR =(0.93 × RFS HR) + 0.14;with RFS 95%CI(0.48-1.38),with P = 0.007.CONCLUSION This association suggests that RFS could work as a putative surrogate endpoint of OS in this population,avoiding bigger,longer and more resource-consuming trials.The OS could be assumed based on RFS and our model could be useful to better estimate sample size calculations of phase Ⅲ trials of CRLM aiming for OS.
AIM To verify either recurrence-free survival (RFS) surrogates overall survival (OS) in phase Ⅲ trials for resectable colorectal liver metastases (CRLM) .METHODS MEDLINE, EMBASE, and Scopus databases were consulted. Eligible studies were phase Ⅲ trials testing any type of systemic therapy (neoadjuvant, adjuvant or perioperative) added to surgery in patients with resectable CRLM.A linear regression model based on hazard ratios (HR) of OS and RFS was performed .RESULTS Of 3059 studies, 5 phase Ⅲ trials (1162 patients) were included for analyzes. A linear regression weighted by each trial was used to estimate the association between each HR and RFS. The originated formula was: OS HR = (0.93 × RFS HR) + 0.14; with RFS 95% CI (0.48-1.38 ), with P = 0.007.CONCLUSION This Association suggests that RFS could work as a putative surrogate endpoint of OS in this population ,dows bigger, longer and more resource-consuming trials. The OS could be based based on RFS and our model could be useful to better esti mate sample size calculations of phase Ⅲ trials of CRLM aiming for OS.